HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization
. The study determined the expression of cancer antigen (CA) 125 and HER‐2 in 45 borderline ovarian tumors (BOTs) and investigated the correlation of these biologic markers with histologic type, clinical stage, and outcome. The level of CA 125 protein was assessed using DAKO's M‐11 clone antibo...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2004-11, Vol.14 (6), p.1078-1085 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1085 |
|---|---|
| container_issue | 6 |
| container_start_page | 1078 |
| container_title | International journal of gynecological cancer |
| container_volume | 14 |
| creator | Heinrich, J. K. R. Böttcher‐Luiz, F. Andrade, L. L. A. Davidson, S. Bonds, L. Stephens, J. Varella‐Garcia, M. |
| description | .
The study determined the expression of cancer antigen (CA) 125 and HER‐2 in 45 borderline ovarian tumors (BOTs) and investigated the correlation of these biologic markers with histologic type, clinical stage, and outcome. The level of CA 125 protein was assessed using DAKO's M‐11 clone antibody in immunohistochemistry (IHC) assays (Carpinteria, CA). The HER‐2 protein expression was assessed in IHC assays using the HercepTest (DAKO), and the HER‐2 gene copy number per cell was investigated through fluorescence in situ hybridization (FISH) assays using VYSIS' PathVysion DNA Probe (Downers Grove, IL). Expression of the CA 125 protein was detected in 49% of the samples (22 out of 45 tumors) and significantly associated with the serous histologic type. However, CA 125 expression did not associate with clinical stage or outcome. Protein overexpression or gene amplification of HER‐2 was not found. However, abnormal FISH results were detected in 16% (seven out of 45 patients) of specimens comprising extranumerary copies of HER‐2 and/or chromosome 17 per cell. Abnormal FISH results were found to be independent of CA 125 expression and histologic type whereas they positively associate with advanced clinical stage. Our data show that HER‐2 is not altered in BOTs, and the presence of aneusomy for chromosome 17 and HER‐2 may predict tumor progression. |
| doi_str_mv | 10.1111/j.1048-891X.2004.14605.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67141458</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67141458</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4134-db2b92c438b85f72ff5a5cc013982d8b599dabfac3c65f1b59717824d968fa9e3</originalsourceid><addsrcrecordid>eNqNUU1v1TAQjBCIlsJfQD5xy6vXsRPngoSqfqFKSAgkbpbjbIgfTlzspG04cemd38gvwXnvIa74srvWzHg9k2UE6AbSOd1ugHKZyxq-bBilfAO8pGLz8CQ7BsFEDryQT1P_F3SUvYhxSymtGa2fZ0cgRAUlFMfZ49X5x98_fzGix5YYPRoMqZ3sVxwJMEHwTrtZT9aPxI7E3-lg9UgaH1oMzo5IpnnwIZJmIXYY5tH3Nk7e9DikGpadbOdmHzAaTOqrSrTTTPqlCba1P3baL7NnnXYRXx3qSfb54vzT2VV-8-Hy-uzdTW44FDxvG9bUzKTPNVJ0Fes6oYUxFIpaslY2oq5b3XTaFKYUHaS5gkoy3tal7HSNxUn2Zq97G_z3GeOk0poGndMj-jmqsgIOXMgElHugCT7GgJ26DXbQYVFA1RqB2qrVXbW6q9YI1C4C9ZCorw9vzM2A7T_iwfME4HvAvXcThvjNzfcYVI_aTb2ia0qiqvJVFCBN-XrFE-3tgWYdLv-9j7p-f7lriz_16KjX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67141458</pqid></control><display><type>article</type><title>HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Heinrich, J. K. R. ; Böttcher‐Luiz, F. ; Andrade, L. L. A. ; Davidson, S. ; Bonds, L. ; Stephens, J. ; Varella‐Garcia, M.</creator><creatorcontrib>Heinrich, J. K. R. ; Böttcher‐Luiz, F. ; Andrade, L. L. A. ; Davidson, S. ; Bonds, L. ; Stephens, J. ; Varella‐Garcia, M.</creatorcontrib><description>.
The study determined the expression of cancer antigen (CA) 125 and HER‐2 in 45 borderline ovarian tumors (BOTs) and investigated the correlation of these biologic markers with histologic type, clinical stage, and outcome. The level of CA 125 protein was assessed using DAKO's M‐11 clone antibody in immunohistochemistry (IHC) assays (Carpinteria, CA). The HER‐2 protein expression was assessed in IHC assays using the HercepTest (DAKO), and the HER‐2 gene copy number per cell was investigated through fluorescence in situ hybridization (FISH) assays using VYSIS' PathVysion DNA Probe (Downers Grove, IL). Expression of the CA 125 protein was detected in 49% of the samples (22 out of 45 tumors) and significantly associated with the serous histologic type. However, CA 125 expression did not associate with clinical stage or outcome. Protein overexpression or gene amplification of HER‐2 was not found. However, abnormal FISH results were detected in 16% (seven out of 45 patients) of specimens comprising extranumerary copies of HER‐2 and/or chromosome 17 per cell. Abnormal FISH results were found to be independent of CA 125 expression and histologic type whereas they positively associate with advanced clinical stage. Our data show that HER‐2 is not altered in BOTs, and the presence of aneusomy for chromosome 17 and HER‐2 may predict tumor progression.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1111/j.1048-891X.2004.14605.x</identifier><identifier>PMID: 15571613</identifier><language>eng</language><publisher>Oxford, UK; Malden, USA: Blackwell Science Inc</publisher><subject>Adenocarcinoma, Mucinous - metabolism ; Biomarkers, Tumor - metabolism ; borderline ovarian tumors ; CA 125 ; CA-125 Antigen - metabolism ; Case-Control Studies ; Cystadenocarcinoma, Serous - metabolism ; Disease Progression ; Female ; FISH ; Gene Expression Regulation, Neoplastic ; HER‐2 ; Humans ; IHC ; Immunohistochemistry ; In Situ Hybridization, Fluorescence ; Ovarian Neoplasms - metabolism ; Paraffin Embedding ; Predictive Value of Tests ; Receptor, ErbB-2 - metabolism ; Retrospective Studies</subject><ispartof>International journal of gynecological cancer, 2004-11, Vol.14 (6), p.1078-1085</ispartof><rights>Copyright © 2004 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4134-db2b92c438b85f72ff5a5cc013982d8b599dabfac3c65f1b59717824d968fa9e3</citedby><cites>FETCH-LOGICAL-c4134-db2b92c438b85f72ff5a5cc013982d8b599dabfac3c65f1b59717824d968fa9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1048-891X.2004.14605.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1048-891X.2004.14605.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27922,27923,45572,45573</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15571613$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Heinrich, J. K. R.</creatorcontrib><creatorcontrib>Böttcher‐Luiz, F.</creatorcontrib><creatorcontrib>Andrade, L. L. A.</creatorcontrib><creatorcontrib>Davidson, S.</creatorcontrib><creatorcontrib>Bonds, L.</creatorcontrib><creatorcontrib>Stephens, J.</creatorcontrib><creatorcontrib>Varella‐Garcia, M.</creatorcontrib><title>HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>.
The study determined the expression of cancer antigen (CA) 125 and HER‐2 in 45 borderline ovarian tumors (BOTs) and investigated the correlation of these biologic markers with histologic type, clinical stage, and outcome. The level of CA 125 protein was assessed using DAKO's M‐11 clone antibody in immunohistochemistry (IHC) assays (Carpinteria, CA). The HER‐2 protein expression was assessed in IHC assays using the HercepTest (DAKO), and the HER‐2 gene copy number per cell was investigated through fluorescence in situ hybridization (FISH) assays using VYSIS' PathVysion DNA Probe (Downers Grove, IL). Expression of the CA 125 protein was detected in 49% of the samples (22 out of 45 tumors) and significantly associated with the serous histologic type. However, CA 125 expression did not associate with clinical stage or outcome. Protein overexpression or gene amplification of HER‐2 was not found. However, abnormal FISH results were detected in 16% (seven out of 45 patients) of specimens comprising extranumerary copies of HER‐2 and/or chromosome 17 per cell. Abnormal FISH results were found to be independent of CA 125 expression and histologic type whereas they positively associate with advanced clinical stage. Our data show that HER‐2 is not altered in BOTs, and the presence of aneusomy for chromosome 17 and HER‐2 may predict tumor progression.</description><subject>Adenocarcinoma, Mucinous - metabolism</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>borderline ovarian tumors</subject><subject>CA 125</subject><subject>CA-125 Antigen - metabolism</subject><subject>Case-Control Studies</subject><subject>Cystadenocarcinoma, Serous - metabolism</subject><subject>Disease Progression</subject><subject>Female</subject><subject>FISH</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>HER‐2</subject><subject>Humans</subject><subject>IHC</subject><subject>Immunohistochemistry</subject><subject>In Situ Hybridization, Fluorescence</subject><subject>Ovarian Neoplasms - metabolism</subject><subject>Paraffin Embedding</subject><subject>Predictive Value of Tests</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Retrospective Studies</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNUU1v1TAQjBCIlsJfQD5xy6vXsRPngoSqfqFKSAgkbpbjbIgfTlzspG04cemd38gvwXnvIa74srvWzHg9k2UE6AbSOd1ugHKZyxq-bBilfAO8pGLz8CQ7BsFEDryQT1P_F3SUvYhxSymtGa2fZ0cgRAUlFMfZ49X5x98_fzGix5YYPRoMqZ3sVxwJMEHwTrtZT9aPxI7E3-lg9UgaH1oMzo5IpnnwIZJmIXYY5tH3Nk7e9DikGpadbOdmHzAaTOqrSrTTTPqlCba1P3baL7NnnXYRXx3qSfb54vzT2VV-8-Hy-uzdTW44FDxvG9bUzKTPNVJ0Fes6oYUxFIpaslY2oq5b3XTaFKYUHaS5gkoy3tal7HSNxUn2Zq97G_z3GeOk0poGndMj-jmqsgIOXMgElHugCT7GgJ26DXbQYVFA1RqB2qrVXbW6q9YI1C4C9ZCorw9vzM2A7T_iwfME4HvAvXcThvjNzfcYVI_aTb2ia0qiqvJVFCBN-XrFE-3tgWYdLv-9j7p-f7lriz_16KjX</recordid><startdate>200411</startdate><enddate>200411</enddate><creator>Heinrich, J. K. R.</creator><creator>Böttcher‐Luiz, F.</creator><creator>Andrade, L. L. A.</creator><creator>Davidson, S.</creator><creator>Bonds, L.</creator><creator>Stephens, J.</creator><creator>Varella‐Garcia, M.</creator><general>Blackwell Science Inc</general><general>Copyright Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200411</creationdate><title>HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization</title><author>Heinrich, J. K. R. ; Böttcher‐Luiz, F. ; Andrade, L. L. A. ; Davidson, S. ; Bonds, L. ; Stephens, J. ; Varella‐Garcia, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4134-db2b92c438b85f72ff5a5cc013982d8b599dabfac3c65f1b59717824d968fa9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adenocarcinoma, Mucinous - metabolism</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>borderline ovarian tumors</topic><topic>CA 125</topic><topic>CA-125 Antigen - metabolism</topic><topic>Case-Control Studies</topic><topic>Cystadenocarcinoma, Serous - metabolism</topic><topic>Disease Progression</topic><topic>Female</topic><topic>FISH</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>HER‐2</topic><topic>Humans</topic><topic>IHC</topic><topic>Immunohistochemistry</topic><topic>In Situ Hybridization, Fluorescence</topic><topic>Ovarian Neoplasms - metabolism</topic><topic>Paraffin Embedding</topic><topic>Predictive Value of Tests</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Heinrich, J. K. R.</creatorcontrib><creatorcontrib>Böttcher‐Luiz, F.</creatorcontrib><creatorcontrib>Andrade, L. L. A.</creatorcontrib><creatorcontrib>Davidson, S.</creatorcontrib><creatorcontrib>Bonds, L.</creatorcontrib><creatorcontrib>Stephens, J.</creatorcontrib><creatorcontrib>Varella‐Garcia, M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Heinrich, J. K. R.</au><au>Böttcher‐Luiz, F.</au><au>Andrade, L. L. A.</au><au>Davidson, S.</au><au>Bonds, L.</au><au>Stephens, J.</au><au>Varella‐Garcia, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2004-11</date><risdate>2004</risdate><volume>14</volume><issue>6</issue><spage>1078</spage><epage>1085</epage><pages>1078-1085</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>.
The study determined the expression of cancer antigen (CA) 125 and HER‐2 in 45 borderline ovarian tumors (BOTs) and investigated the correlation of these biologic markers with histologic type, clinical stage, and outcome. The level of CA 125 protein was assessed using DAKO's M‐11 clone antibody in immunohistochemistry (IHC) assays (Carpinteria, CA). The HER‐2 protein expression was assessed in IHC assays using the HercepTest (DAKO), and the HER‐2 gene copy number per cell was investigated through fluorescence in situ hybridization (FISH) assays using VYSIS' PathVysion DNA Probe (Downers Grove, IL). Expression of the CA 125 protein was detected in 49% of the samples (22 out of 45 tumors) and significantly associated with the serous histologic type. However, CA 125 expression did not associate with clinical stage or outcome. Protein overexpression or gene amplification of HER‐2 was not found. However, abnormal FISH results were detected in 16% (seven out of 45 patients) of specimens comprising extranumerary copies of HER‐2 and/or chromosome 17 per cell. Abnormal FISH results were found to be independent of CA 125 expression and histologic type whereas they positively associate with advanced clinical stage. Our data show that HER‐2 is not altered in BOTs, and the presence of aneusomy for chromosome 17 and HER‐2 may predict tumor progression.</abstract><cop>Oxford, UK; Malden, USA</cop><pub>Blackwell Science Inc</pub><pmid>15571613</pmid><doi>10.1111/j.1048-891X.2004.14605.x</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2004-11, Vol.14 (6), p.1078-1085 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67141458 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Adenocarcinoma, Mucinous - metabolism Biomarkers, Tumor - metabolism borderline ovarian tumors CA 125 CA-125 Antigen - metabolism Case-Control Studies Cystadenocarcinoma, Serous - metabolism Disease Progression Female FISH Gene Expression Regulation, Neoplastic HER‐2 Humans IHC Immunohistochemistry In Situ Hybridization, Fluorescence Ovarian Neoplasms - metabolism Paraffin Embedding Predictive Value of Tests Receptor, ErbB-2 - metabolism Retrospective Studies |
| title | HER‐2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T03%3A05%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HER%E2%80%902%20and%20cancer%20antigen%20125%20evaluation%20in%20ovarian%20borderline%20tumors%20by%20immunohistochemistry%20and%20fluorescence%20in%20situ%20hybridization&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Heinrich,%20J.%20K.%20R.&rft.date=2004-11&rft.volume=14&rft.issue=6&rft.spage=1078&rft.epage=1085&rft.pages=1078-1085&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1111/j.1048-891X.2004.14605.x&rft_dat=%3Cproquest_cross%3E67141458%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67141458&rft_id=info:pmid/15571613&rfr_iscdi=true |